Quanterix (QTRX) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Quanterix is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.45) per share and revenues of $29.73 million.
• The company's last reported earnings showed a smaller loss than expected, with a negative net margin of 36.82% and a P/E ratio of -4.44.
• Institutional investors own 86.48% of Quanterix's stock, with notable purchases by firms like AQR Capital Management and Goldman Sachs in recent quarters.

Quanterix (NASDAQ:QTRX - Get Free Report) is expected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $29.73 million for the quarter. Quanterix has set its FY 2025 guidance at EPS.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.16. The business had revenue of $30.33 million for the quarter, compared to analysts' expectations of $28.27 million. Quanterix had a negative net margin of 36.82% and a negative return on equity of 15.07%. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quanterix Trading Down 3.1%

NASDAQ:QTRX traded down $0.19 during trading hours on Wednesday, reaching $5.78. 120,623 shares of the company traded hands, compared to its average volume of 773,959. The business's 50-day moving average price is $5.97 and its two-hundred day moving average price is $6.49. The stock has a market capitalization of $288.46 million, a P/E ratio of -4.44 and a beta of 1.07. Quanterix has a 1 year low of $4.05 and a 1 year high of $15.85.

Insider Transactions at Quanterix

In other news, Director William P. Donnelly bought 93,113 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were bought at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the completion of the transaction, the director owned 139,094 shares of the company's stock, valued at approximately $756,671.36. This represents a 202.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David R. Walt acquired 123,990 shares of the firm's stock in a transaction on Friday, June 13th. The shares were bought at an average price of $6.14 per share, for a total transaction of $761,298.60. Following the completion of the transaction, the director owned 1,866,933 shares of the company's stock, valued at approximately $11,462,968.62. This trade represents a 7.11% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 463,113 shares of company stock worth $2,625,444 over the last quarter. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. AQR Capital Management LLC grew its stake in Quanterix by 204.4% in the first quarter. AQR Capital Management LLC now owns 98,990 shares of the company's stock worth $644,000 after purchasing an additional 66,470 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Quanterix by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 349,696 shares of the company's stock valued at $2,277,000 after purchasing an additional 59,655 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Quanterix by 26.3% during the 1st quarter. Royal Bank of Canada now owns 170,745 shares of the company's stock valued at $1,112,000 after purchasing an additional 35,509 shares during the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Quanterix by 4.2% during the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company's stock valued at $380,000 after purchasing an additional 2,366 shares during the last quarter. Institutional investors own 86.48% of the company's stock.

Analyst Ratings Changes

QTRX has been the subject of several recent analyst reports. Canaccord Genuity Group decreased their price target on Quanterix from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Leerink Partners restated a "market perform" rating and issued a $8.00 price target (down previously from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. Wall Street Zen lowered Quanterix from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Leerink Partnrs lowered Quanterix from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $13.50.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.